Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Palazestrant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olema Oncology to Present Palazestrant, OP-3136 Data in 2026
    Olema Oncology to Present Palazestrant, OP-3136 Data in 2026

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257678/0/en/Olema-Oncology-to-Present-Preclinical-Data-for-Palazestrant-and-OP-3136-at-the-2026-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Olema Oncology Reveals 2025 Financial Results
    Olema Oncology Reveals 2025 Financial Results

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256109/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177971/0/en/Olema-Oncology-to-Present-Trial-in-Progress-Poster-for-Phase-3-OPERA-02-Trial-of-Palazestrant-Plus-Ribociclib-at-SABCS-2025.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168941/0/en/Olema-Oncology-Announces-New-Data-from-the-Phase-1b-2-Trial-of-Palazestrant-Plus-Ribociclib-in-ER-HER2-Metastatic-Breast-Cancer-at-ESMO-2025.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    Olema Oncology, Pfizer Partner to Combine Palazestrant
    Olema Oncology, Pfizer Partner to Combine Palazestrant

    02 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/02/3142485/0/en/Olema-Oncology-Announces-New-Clinical-Trial-Agreement-with-Pfizer-to-Combine-Palazestrant-with-Atirmociclib-in-ER-HER2-Metastatic-Breast-Cancer.html

    GLOBENEWSWIRE
    02 Sep 2025
    Share Share
    Olema Oncology Reports Q2 2024 Results And Corporate Update
    Olema Oncology Reports Q2 2024 Results And Corporate Update

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925417/0/en/Olema-Oncology-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.